Stevens Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Stevens Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-34,121	Closed	-$307K	–	225
2020 Q3	$307K	Buy	+34,121	New	+$361K	0.11%	96
2019 Q1	–	Sell	-63,429	Closed	-$978K	–	886
2018 Q4	$978K	Buy	+63,429	New	+$1.3M	0.05%	385
2017 Q2	–	Sell	-10,227	Closed	-$328K	–	1071
2017 Q1	$328K	Buy	+10,227	New	+$349K	0.01%	679
2016 Q4	–	Sell	-42,863	Closed	-$1.97M	–	1102
2016 Q3	$1.97M	Sell	42,863 -8,053	-16%	-$420K	0.08%	290
2016 Q2	$2.56M	Buy	50,916 +25,700	+102%	+$1.37M	0.1%	255
2016 Q1	$1.35M	Buy	+25,216	New	+$1.48M	0.05%	363
2015 Q4	–	Sell	-42,063	Closed	-$2.38M	–	1139
2015 Q3	$2.38M	Buy	42,063 +6,712	+19%	+$435K	0.11%	204
2015 Q2	$2.09M	Buy	+35,351	New	+$2.18M	0.08%	275
2014 Q1	–	Sell	-20,972	Closed	-$841K	–	1320
2013 Q4	$841K	Sell	20,972 -41,986	-67%	-$1.65M	0.02%	513
2013 Q3	$2.38M	Buy	+62,958	New	+$2.46M	0.07%	308

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Stevens Capital Management's TEVA Position: Q4 2020 in Review

Stevens Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 34,121 shares — an estimated $307K sold.

Stevens Capital Management first reported a position in TEVA in Q3 2013 and held it in 10 quarters. The position peaked at $2.56M in Q2 2016. 449 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

Stevens Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Stevens Capital Management sold 34,121 Teva Pharmaceuticals shares in Q4 2020, an estimated $307K.
Stevens Capital Management first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 10 quarters.
Stevens Capital Management's Teva Pharmaceuticals position peaked at $2.56M in Q2 2016.
449 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Stevens Capital Management's 13F filing for Q4 2020, filed 8 Feb 2021.